Astrazeneca (AZN) Intangibles (2009 - 2026)
Astrazeneca (AZN) posted quarterly Intangibles of $37.7 billion for Q2 2026, down 0.53% year-over-year from $37.9 billion in Q2 2025, and up 2.21% quarter-over-quarter from $36.9 billion in Q1 2026.
Astrazeneca (AZN) Intangibles (2009 - 2026) Analysis & Trends
Astrazeneca's Intangibles history runs 18 years deep, the most recent figure standing at $37.7 billion for Q2 2026.
- In Q2 2026, Intangibles fell 0.53% year-over-year to $37.7 billion; the TTM figure through Jun 2026 stood at $37.7 billion (down 0.53% YoY), while the FY2025 annual figure was $37.8 billion, up 1.8% from the prior year.
- Intangibles for Q2 2026 stood at $37.7 billion, up from $36.9 billion in the prior quarter.
- The five-year high for Intangibles was $73.5 billion in Q4 2023, with the low at $36.9 billion in Q1 2026.
- The 5-year median for Intangibles is $38.6 billion (2023), against an average of $40.5 billion.
- The sharpest annual moves came in 2022 and 2024: Intangibles soared 156.68% in 2022, then sank 49.41% in 2024.
- Astrazeneca's Intangibles stood at $39.3 billion in 2022, then soared by 86.96% to $73.5 billion in 2023, then tumbled by 49.41% to $37.2 billion in 2024, then climbed by 1.8% to $37.8 billion in 2025, then declined by 0.33% to $37.7 billion in 2026.
- Business Quant data shows AZN's Intangibles at $37.7 billion in Q2 2026, $36.9 billion in Q1 2026, and $37.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 30.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.72 Bn |
| Mar 31, 2026 | 36.91 Bn |
| Dec 31, 2025 | 37.85 Bn |
| Sep 30, 2025 | 38.19 Bn |
| Jun 30, 2025 | 37.93 Bn |
| Mar 31, 2025 | 37.55 Bn |
| Dec 31, 2024 | 37.18 Bn |
| Sep 30, 2024 | 39.39 Bn |
| Jun 30, 2024 | 39.43 Bn |
| Mar 31, 2024 | 38.83 Bn |
| Dec 31, 2023 | 73.49 Bn |
| Sep 30, 2023 | 37.69 Bn |
| Jun 30, 2023 | 38.33 Bn |
| Mar 31, 2023 | 39.29 Bn |
| Dec 31, 2022 | 39.31 Bn |
| Sep 30, 2022 | 39.59 Bn |
| Jun 30, 2022 | 39.90 Bn |
| Mar 31, 2022 | 41.27 Bn |
| Dec 31, 2021 | 70.63 Bn |
| Sep 30, 2021 | 44.10 Bn |